Biocon arm’s partnership with Bristol Myers Squibb, extends
Syngene International, Biocon’s contract research arm has extended its current drug discovery and development with US based Bristol-Myers Squibb till 2026. In a BSE filing Syngene...
Download Unicorn Signals App
Powered By EquityPandit
